Perspectives & Insights

At Novavax, we are expanding our pipeline to realize the potential of our cutting-edge Technology Platform. With our protein-based nanoparticles and Matrix-M® adjuvant, we have a strong foundation for innovation.

Kumar Singh Saikatendu, Head of our Translational Medicine team shares what excites him for the future of the Company, including the potential of preclinical vaccine candidates to address unmet needs, as well as the application of artificial intelligence and machine learning to accelerate the development of these candidates.